NCT07491328

Liquid Biopsy in Paraneoplastic Neurological Syndromes

Liquid Biopsy in Paraneoplastic Neurological Syndromes With High- and Intermediate-Risk Antibodies

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 60 (estimated)
• Sponsor: Heinrich-Heine University, Duesseldorf · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main objective of the study is to assess whether circulating tumor cells (CTCs) can be detected in the peripheral blood of patients with paraneoplastic neurological syndromes (PNS) by diagnostic leukapheresis (DLA) combined with the CELLSEARCH® System during clinical routine workup. If CTCs can be identified, a detailed molecular genetic analysis will be performed to characterize mutations in oncogenes and tumor suppressor genes. In addition, the study aims to analyze cell-free DNA (cfDNA) in serum of patients. Individuals with PNS and high- or intermediate-risk or GAD65-antibodies with a detectable tumor (PNS+T), PNS patients with high- or intermediate-risk or GAD65-antibodies without detectable tumor (PNS w/o T), and matched tumor patients without PNS (T w/o PNS) will be included in the study.

Conditions

• Paraneoplastic Neurological Syndromes

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	CTC & ctDNA analysis	Analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in the peripheral blood

Timeline

• Start date: 2023-05-20
• Primary completion: 2030-12-30
• Completion: 2030-12-30
• First posted: 2026-03-24
• Last updated: 2026-03-24

Locations

1 site across 1 country: Germany